Pseudoprogression of Glioblastoma Multiforme After Chemoradiation Therapy: Diagnosis by 11C-Methionine Positron Emission Tomography (PET)

Extracranial metastasis of multiforme glioblastoma detected by 11C-methionine brain PET/CT.

The effect of fasting on Positron Emission Tomography (PET) imaging

As a nuclear approach, Positron Emission Tomography (PET) is a functional imaging technique which is based on the detection of gamma ray pairs emitted by a positron-emitting radionuclide. There are certain limitations to this technique such as normal tissue uptake. Therefore, it has been recommended that patients prepare before scanning. Fasting for a short while before PET imaging is an exampl...

Positron Emission Tomography ( PET )

The principle of image formation in tomography is summarised. The principle ofpositron electron annihilation is introduced. The principle of coincidence techniques is illustrated. Detector development and perspectives for positron emission tomography (PET) instrumentation for medical research is presented. The physical processes in in positron annihilation, photon scattering and tomograph desig...

[PET using 11C-methionine in recognition of pseudoprogression in cerebral glioma after combined treatment].

The purpose of the study was to evaluate the value of PET using 11C-methionine (PET-Met) for distinction between true glioma progression and pseudoprogression (PsPr). 72 patients with treated cerebral glioma investigated by PET-Met were identified from prospective database. Entry criteria included new or progressive MR imaging enhancing lesions within first 6 months after irradiation and defini...

Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.

Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge. Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning. Ten patients were enrolled. Eligibility criteria included pathologic diagnosis of GBM, age >or=18 years, and KPS >or=60. Patie...